A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
一项评估艾菲莫司非明α单次给药在中国、日本和白人/欧洲血统健康受试者中的安全性、耐受性、药代动力学和免疫原性的1期、随机、安慰剂对照、双盲、平行组研究
This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Auckland、新西兰、1010
- GSK Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Participants who are generally healthy as determined by medical evaluation
- Body weight at least 50.0 kilograms (kg) for male participants or at least 45.0 kg for female participants
- Body mass index (BMI) within the range of 18.0 to 28.0 kilograms per square meter (kg/m^2) (inclusive)
- Male and female participants
- Participants of Chinese ancestry are eligible if born in mainland China, Hong Kong, or Taiwan, and descendant of 2 ethnic Chinese parents and 4 ethnic Chinese grandparents; and have lived outside China, Hong Kong, or Taiwan for less than 10 years at the time of screening.
- Participants of Japanese ancestry are eligible if born in Japan and descendant of 2 ethnic Japanese parents and 4 ethnic Japanese grandparents; and have lived outside Japan for less than 10 years at the time of screening.
- Participants of White/European ancestry are eligible if self-identified as being of White/European ancestry, (that is [i.e.], from the original peoples of Europe) irrespective of current place of residence; and descendant of 2 parents and 4 grandparents of White/European ancestry (i.e., from the original peoples of Europe) irrespective of place of birth or current place of residence.
Exclusion Criteria:
- History or presence of disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
- Current or chronic history of liver or biliary disease with the exception of Gilbert's syndrome or asymptomatic gallstones.
- History of pancreatic injury, pancreatitis or other pancreatic disease; history of Type one Diabetes Mellitus (T1DM) or positive glutamic acid decarboxylase auto-antibodies, or major Type two Diabetes Mellitus (T2DM) complications including severe gastroparesis and autonomic neuropathy.
- Abnormal blood pressure (defined as systolic Blood Pressure [BP] more than equal [>=]140 millimeters of mercury [mmHg] or diastolic BP >=90 mmHg measured based on the average of triplicate BP readings).
- History of metabolic bone disorders including osteoporosis, osteopenia, or osteomalacia.
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years.
- Alanine transaminase (ALT) more than (>)1.5 * upper limit of normal (ULN).
- Total bilirubin >1.5 * ULN
- Known bleeding disorder.
- History of immunodeficiency diseases, including a positive test result for human immunodeficiency virus (HIV).
- Corrected QT Interval using Fridericia's Formula (QTcF) >=450 millisecond (msec)(male) or >=470 msec (female) at Screening Visit based on the average of triplicate ECGs.
- Use of statins, other lipid lowering medications or hypertension medications unless on a stable dose for at least 3 months.
- Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever was longer; or longer if required by local regulations.
- Participants who have received native FGF21 or a FGF21 analog at any time in the past.
- Intended use of over the counter (OTC) or prescription medication (including herbal medications) within 7 days prior to dosing and for the duration of study participation.
- Live vaccine within 14 days prior to dosing and non-live vaccines for 7 days prior study dosing.
- Current enrolment or participation in another clinical trial within the last 30 days before signing consent of current study.
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis C antibody at screening or within 3 months prior to the first dose of study intervention
- A positive pre-study drug/alcohol screen
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Efimosfermin alfa in participants of Chinese Ancestry
Healthy participants of Chinese ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
实验性的:Efimosfermin alfa in participants of Japanese Ancestry
Healthy participants of Japanese ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
实验性的:Efimosfermin alfa in participants of White/European Ancestry
Healthy participants of White/European ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
安慰剂比较:Placebo in participants of Chinese Ancestry
Healthy participants of Chinese ancestry will be randomized to receive Placebo. |
Placebo to be administered |
|
安慰剂比较:Placebo in participants of Japanese Ancestry
Healthy participants of Japanese ancestry will be randomized to receive Placebo. |
Placebo to be administered |
|
安慰剂比较:Placebo in participants of White/European Ancestry
Healthy participants of White/European ancestry will be randomized to receive Placebo. |
Placebo to be administered |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
出现不良事件(AEs)、治疗相关不良事件及严重不良事件(SAEs)的参与者人数
大体时间:最多 90 天
|
最多 90 天
|
|
出现血液学、化学及尿液分析参数临床显著变化的参与者数量
大体时间:最多 90 天
|
最多 90 天
|
|
12导联心电图(ECG)出现临床显著变化的受试者数量
大体时间:最多 90 天
|
最多 90 天
|
|
出现生命体征临床显著变化的参与者人数
大体时间:最多90天
|
最多90天
|
|
从时间零到最后一个可量化浓度时间的血清药物浓度-时间曲线下面积(AUC[0-t]),针对艾菲莫斯菲尔明α
大体时间:最长90天
|
最长90天
|
|
efimosfermin alfa 从时间零外推至无穷大的血清药物浓度-时间曲线下面积 (AUC[0-inf])
大体时间:长达90天
|
长达90天
|
|
从efimosfermin alfa血清浓度-时间数据直接测定的最大血清药物浓度观察值(Cmax)
大体时间:长达90天
|
长达90天
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
efimosfermin alfa 达到最大观察血清药物浓度的时间(Tmax)
大体时间:最多90天
|
最多90天
|
|
efimosfermin alfa 的表观终末相半衰期 (t1/2)
大体时间:长达90天
|
长达90天
|
|
efimosfermin alfa 从零时到90天血清药物浓度-时间曲线下面积[AUC(0-90天)]
大体时间:长达90天
|
长达90天
|
|
efimosfermin alfa 最后可量化血浆药物浓度时间(Tlast)
大体时间:最多 90 天
|
最多 90 天
|
|
表观清除率 (CL/F) 的艾菲莫斯费明阿尔法
大体时间:最长90天
|
最长90天
|
|
依非莫司非明α的表观分布容积 (Vz/F)
大体时间:长达90天
|
长达90天
|
|
Area under the serum drug concentration versus time curve from time zero to 45 days [AUC(0-45days)] of efimosfermin alfa
大体时间:Up to 45 days
|
Up to 45 days
|
|
Area under the serum drug concentration versus time curve from time zero to 60 days [AUC(0-60days)] of efimosfermin alfa
大体时间:Up to 60 days
|
Up to 60 days
|
合作者和调查者
调查人员
- 研究主任:GSK Clinical Trials、GlaxoSmithKline
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 301158
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD 共享时间框架
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD 共享访问标准
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.